Rosiglitazone is effective and well tolerated in patients ≥65 years with type 2 diabetes

被引：0
|
作者：
Beebe, K
Patel, J
机构：
来源：
DIABETES | 1999年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0479
引用
收藏
页码：A111 / A111
页数：1
相关论文
共 50 条
  • [21] The effect of rosiglitazone on gluconeogenesis in patients with Type 2 diabetes
    Gastaldelli, A
    Miyazaki, Y
    Matsuda, M
    Pettiti, M
    Santini, E
    Ferrannini, E
    Defronzo, RA
    DIABETOLOGIA, 2002, 45 : A5 - A5
  • [22] Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes
    Jones, T
    Jones, NP
    Sautter, M
    DIABETOLOGIA, 2000, 43 : A191 - A191
  • [23] Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes.
    Cranmer, H
    Jones, NP
    Patwardhan, R
    DIABETOLOGIA, 1999, 42 : A228 - A228
  • [24] Rosiglitazone monotherapy is effective in patients with type 2 diabetes (vol 86, pg 280, 2001)
    Lebovitz, HE
    Dole, JF
    Patwardhan, R
    Rappaport, EB
    Freed, MI
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04): : 1659 - 1659
  • [25] Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM)
    Krishnan, Amrita
    Cohen, Adam
    Trudel, Suzanne
    Spencer, Andrew
    Lesokhin, Alexander
    Wong, Chihunt
    Choeurng, Voleak
    Cooper, James
    Sumiyoshi, Teiko
    Goodman, Grant
    Jin, Hyun Yong
    Sheikh, Semira
    Harrison, Simon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S42 - S43
  • [26] Vildagliptin is effective and well-tolerated when it is added to a hypoglycemic sulfamide in type 2 diabetic patients
    Dejager, S.
    Reigneau, O.
    Garber, A. J.
    Baron, M.
    DIABETES & METABOLISM, 2008, 34 : A57 - A57
  • [27] Once-daily sitagliptin monotherapy provides effective glycemic control over 54 weeks and is well tolerated in patients with type 2 diabetes
    Aschner, Pablo
    Lunceford, Jared
    Williams-Herman, Debora
    DIABETES, 2007, 56 : A553 - A553
  • [28] Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
    Nowicki, M.
    Rychlik, I.
    Haller, H.
    Warren, M. L.
    Suchower, L.
    Gause-Nilsson, I.
    DIABETES OBESITY & METABOLISM, 2011, 13 (06): : 523 - 532
  • [29] Metformin/glyburide is safe and well tolerated as first-line therapy in patients with type 2 diabetes
    Davidson, J
    Schneider, S
    Garber, A
    Merten, J
    DIABETES, 2000, 49 : A356 - A356
  • [30] Sitagliptin, a selective DPP4 inhibitor, is well tolerated in patients with type 2 diabetes: Pooled analysis of 5141 patients in clinical trials for up to 2 years
    Stein, Peter P.
    Williams-Herman, Debora
    Khatami, Hootan
    Meininger, Gary
    Round, Elizabeth
    Sheng, Danielle
    Sanchez, Matilde
    Lunceford, Jared
    Kaufman, Keith D.
    Amatruda, John M.
    DIABETES, 2007, 56 : A142 - A143
12345